The psychotherapeutic effects of estrogens

Gynecological Endocrinology

Volumn 12, Issue 5, 1998, Pages 353-365

  Panay, N ^a   Studd, J W W ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Chronic fatigue syndrome; Estrogens; Menopausal depression; Postnatal depression

Indexed keywords

ESTROGEN;

BEHAVIOR; CENTRAL NERVOUS SYSTEM; CHRONIC FATIGUE SYNDROME; COGNITION; DEMENTIA; DEPRESSION; FEMALE; HUMAN; MOOD; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW;

EID: 0031798073     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.3109/09513599809012838     Document Type: Review

References (75)

1. Maggi A, Perez J. Role of female gonadal hormones in the CNS: clinical and experimental aspects. Life Sci 1985;37:893-906
2. Sherwin BB. Hormones, mood and cognitive functioning in postmenopausal women. Obstet Gynecol 1996;87:20-6
3. Crowley WR. Effects of ovarian hormones on norepinephrine and dopamine turnover in individual hypothalamic and extrahypothalamic nuclei. Neuroendocrinology 1982;34:381-6
4. Luine VN, McEwen BS. Effect of estradiol on turnover of type A monoamine oxidase in brain. J Neurochem 1977;28:1221-7
5. Aylward M. Plasma tryptophan levels and mental depression in postmenopausal subjects. Effects of oral piperazine oestrone sulphate. IRCS Med Sci 1973;(i):30-4
6. Pitt B. Atypical depression following childbirth. Br J Psych 1968;114:1325-35
7. Henderson A, Studd JWW. Oestrogens and postnatal depression. Cont Rev Obstet Gynaecol 1995;7: 90-6
8. Wagner HR, Davis JN. Decreased beta-adrenoceptor responses in female rat are eliminated by ovariectomy: correlation of 3H-dihydroalprenolol binding and catecholamine stimulated cAMP levels. Brain Res 1980;201:235-9
9. Harris B, Johns S, Fung H, et al. The hormonal environment of postnatal depression. Br J Psych 1989;154:660-7
10. Harris B, Lovett L, Newcombe R, et al. Maternity blues and major endocrine changes: Cardiff puerperal mood and hormone study II. Br Med J 1994; 308:49-53
11. Alder EM, Cox JL. Breast feeding and postnatal depression. J Psychosom Res 1983;27:139-44
12. Henderson A, Gregoire AJP, Kumar R, et al. The treatment of severe postnatal depression with oestradiol skin patches. Lancet 1991;i:816
13. Gregoire AJP, Kumar R, Everitt D, et al. Transdermal oestrogen is an effective treatment for severe postnatal depression. Lancet 1996;347:930-3
14. Magos AL, Studd JWW. The premenstrual syndrome. In JWW Studd, cd. Progress in Obstetrics and Gynaecology, Vol. 4. London: Churchill Livingstone, 1984:334-50
15. Reid RL. Premenstrual syndrome. N Engl J Med 1991;324:1208-10
16. Studd JWW. Premenstrual tension syndrome. Br Med J 1979;i:410
17. Watts JF, Butt WR, Logan Edwards R. A clinical trial using for the treatment of premenstrual tension. Br J Obstet Gynaecol 1987;94:30-4
18. Leather AT, Studd JWW, Watson NR, et al. The prevention of bone loss in young women treated with GnRH analogues with 'add-back' estrogen therapy. Obstet Gynecol 1993;81:104-7
19. Magos AL, Brincat M, Studd JWW. Treatment of the premenstrual syndrome by subcutaneous oestradiol implants and cyclical oral norethisterone: placebo controlled study. Br Med J 1986;292: 1629-33
20. Watson NR, Studd JWW, Riddle AF, et al. Suppression of ovulation by transdermal oestradiol patches. Br Med J 1988;297:900-1
21. Watson NR, Studd JWW, Savvas M, et al. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet 1989;i:730-4
22. Smith RNJ, Studd JWW, Zamblera D, et al. A randomised comparison over 8 months of 100 μg and 200 μg twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. Br J Obstet Gynaecol 1995; 102:475-84
23. Smith RNJ, Studd JWW. Oestrogen and depression in women. In RA Lobo, ed. Treatment of the Postmenopausal Woman. New York: Raven Press, 1994:129-36
24. Montgomery JC, Brincat M, Studd JWW, et al. Effect of oestrogen and testosterone implants on psychological disorders in the climacteric. Lancet 1987;i:297-9
25. Ditkoff EC, Crary WG, Cristo M, et al. Estrogen improves psychological functioning in asymptomatic postmenopausal women. Obstet Gynecol 1991; 78:991-5
26. Klaiber EL, Broverman DM, Vogel W, et al. Estrogen replacement therapy for severe persistent depression in women. Arch Gen Psych 1979;36: 550-4
27. Graham CA, Sherwin BB. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res 1992;36:257-66
28. Slap GB. Oral contraceptives and depression: impact, prevalence and cause. J Adolesc Health Care 1981;2:53-64
29. Forrest ARW. Cyclical variations in mood in normal women taking oral contraceptives. Br Med J 1979;2(6202):1403
30. Shaarawy M, Fayad M, Nagui AR, et al. Serotonin metabolism and depression in oral contraceptive users. Contraception 1982;26:193-204
31. Cullberg J. Mood changes and menstrual symptoms with different gestagen/estrogen combinations. A double blind comparison with placebo. Acta Psych Scand 1972;236:1-46
32. Backstrom T, Smith S, Lothian H, et al. Prolonged follicular phase and depressed gonadotrophins following hysterectomy and corpus luteectomy in women with premenstrual tension syndrome. Clin Endocrinol 1985;22:723-32
33. Backstrom T, Lindhe B-A, Cavalli-Bjorkman B, et al. Effects of oral contraceptives on mood: a randomised comparison of three phasic and monphasic preparations. Contraception 1985;46:253-68
34. Fleming O, Seager CP. Incidence of depressive symptoms in users of the oral contraceptive. Br J Psych 1978;132:431-40
35. Warner P, Bancroft J. Mood, sexuality, oral contraceptives and the menstrual cycle. J Psychosom Research 1988;32:417-27
36. Kay CR. The Royal College of General Practitioner's oral contraceptive study: some recent observations. Clin Obstet Gynaecol 1984;11:759-86
37. Daly E, Gray A, Barlow D, et al. Measuring the impact of menopausal symptoms on quality of life. Br Med J 1993;307:836-40
38. Limouzin-Lamothe M, Mairon N, LeGal J, et al. Quality of life after the menopause: influence of hormone replacement therapy. Am J Obstet Gynecol 1991;78:991-5
39. Best N, Rees M, Barlow D, et al. Effect of estradiol implant on noradrenergic function and mood in menopausal patients. Psychoneurendocrinology 1992; 17:87-93
40. Sherwin B, Surany-Cadotte BE. Up regulatory effect of estrogen on platelet 3H-imipramine binding sites in surgically menopaused women. Biol Psych 1990;28:339-48
41. Coope J, Thomson J, Poller L. Effect of 'natural estrogen' replacement therapy on menopausal symptoms and blood clotting. Br Med J 1975;4: 139-43
42. Shapira B, Oppenheim G, Zohar J, et al. Lack of efficacy of estrogen supplementation to imipramine in resistant female depressives. Biol Psych 1985;20:570-83
43. Studd JWW, Collins WP, Chakravarti S, et al. Oestradiol and testosterone implants in the treatment of psychosexual problems in the postmenopausal woman. Br J Obstet Gynaecol 1977; 84:314-5
44. Bancroft J, Sherwin BE, Alexander GN, et al. Oral contraceptive, androgens, and the sexuality of young women: 1. A comparison of sexual experience, sexual attitude and gender role in oral contraceptive users and non-users. Arch Sex Behav 1991; 20:106
45. McCoy N, Davidson JM. A longitudinal study of the effects of menopause on sexuality. Maturitas 1985;7:203
46. Myers LS, Dixen J, Morrissette M, et al. Effects of estrogen, androgen and progestin on sexual psychophysiology and behaviour in post-menopausal women. J Clin Endocrinol Metab 1990; 70:1124-31
47. Burger H, Hailes J, Nelson J, et al. Effect of combined implants of estradiol and testosterone on libido in postmenopausal women. Br Med J 1984; 294:936-7
48. Davis SR, McCloud F, Strauss BJG, et al. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1994; 21:227-36
49. Holst J, Backstrom T, Hammarback S, et al. Progestogen addition during oestrogen replacement therapy - effects on vasomotor symptoms and mood. Maturitas 1989;11:13-20
50. Magos AL, Brewster E, Studd JWW, et al. The effects of norethisterone in postmenopausal women on oestrogen replacement therapy: a model for premenstrual syndrome. Br J Obstet Gynaecol 1986;93:1290-6
51. Studd JWW. Complications of hormone replacement therapy in postmenopausal women. J R Soc Med 1992;85:376-8
52. Raudaskoski TH, Lahti EI, Kauppila AJ, et al. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses. Am J Obstet Gynecol 1995;172:114-9
53. Suhonen SP, Holmstrom T, Allonen HO, et al. Intrauterine and sub-dermal progestin administration in postmenopausal hormone replacement therapy. Fertil Steril 1995;63:336-42
54. Panay N, Studd JWW, Thomas A, et al. Prospective study of menopausal women on subcutaneous oestradiol, switched to the levonorgestrel releasing intrauterine system because of oral progestogen intolerance. Acta Obstet Gynecol Scand 1997;76:56
55. McEwen BS. Ovarian steroids have diverse effects on brain structure and function. In Berg G, Hammar M, eds. The Modern Management of the Menopause. New York: Parthenon Publishing Group 1993:269-78
56. Fillit H. Estrogens in the pathogenesis and treatment of Alzheimer's disease in postmenopausal women. Ann NY Acad Sci 1994;743:233-8
57. Phillips S, Sherwin BB. Effects of estrogen on memory function in surgically menopaused women. Psychoneuroendocrinology 1991;17:485-95
58. Barrett-Connor E, Kritz-Silverstein D. Estrogen replacement therapy and cognitive function in older women. J Am Med Assoc 1993;260:2637-41
59. Kampen DL, Sherwin BB. Estrogen use and verbal memory in healthy postmenopausal women. Obstet Gynecol 1994;83:979-83
60. Funk JL, Mortel KF, Meyer JS. Effects of estrogen replacement therapy on cerebral perfusion and cognition amongst postmenopausal women. Dementia 1991;2:268-72
61. Butler RN, Aronheim H, Fillet H, et al. Vascular dementia: stroke prevention takes on new urgency. Geriatrics 1993;48:32-4
62. Bueb LP, Hob PR, Bouras C, et al. Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders. Acta Neuropathol 1994;87:469-80
63. Jaffe AB, Toran-Allerand D, Greengard P, et al. Estrogen regulates metabolism of Alzheimer amyloid β precursor protein. J Biol Chem 1994;269: 13065-8
64. Toran-Allerand CD, Miranda RC, Bentham MR, et al. Estrogen receptors colocalize with low affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc Nat Acad Sci 1992; 89:4668-72
65. Singh M, Meyer EM, Millard WJ, et al. Ovarian steroid deprivation results in a reversible learning impairment and compromized cholinergic function in female Sprague Dawley rats. Brain Res 1994; 644:305-12
66. Simkins JW, Singh M, Bishop J. The potential role for estrogen replacement therapy in the treatment of cognitive decline and neurodegeneration associated with Alzheimer's disease. Neurobiol Age 1994; 15(Suppl.2):195-7
67. Lobo RA. Benefits and risks of estrogen replacement therapy. Am J Obstet Gynecol 1995;173: 982-90
68. Henderson VW, Paganini-Hill A, Emanuel CK, et al. Estrogen replacement therapy in older women. Arch Neurol 1994;51:896-900
69. Okura T, Isse K, Akazawa K, et al. Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer type: seven case reports. Dementia 1995;6:99-107
70. Fillit H. Estrogens in the pathogenesis and treatment of Alzheimer's disease in post-menopausal women. Ann NY Acad Sci 1994;743: 234-9
71. Honjo H, Ogino Y, Naithoh K, et al. In vivo effects by estrone sulphate on the central nervous system -senile dementia (Alzheimer's type). J Steroid Biochem 1989;34:521-5
72. Ming-Xin T, Jacobs D, Stern Y, et al. Effect of oestrogen during the menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348: 429-32
73. Report of the Joint Working Group of the Royal College of Physicians, Psychiatrists and General Practitioners. Chronic Fatigue Syndrome. Cr54. London: Royal College of Physicians, October 1996
74. Studd JWW, Panay N. Chronic fatigue syndrome. Lancet 1996;348:1384
75. Studd JWW. Gender and depression. Lancet 1992; 340:794